Substance Use Disorders in HIV People of Cameroon
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02356185|
Recruitment Status : Unknown
Verified February 2015 by Jean Joel R. Bigna, Goulfey Health District Unit.
Recruitment status was: Not yet recruiting
First Posted : February 5, 2015
Last Update Posted : February 18, 2015
Data are scarce concerning injecting drug use (IDU) and alcohol consumption among HIV-infected people on highly active antiretroviral treatment (HAART) in Cameroon. The aim of this study is to determine the prevalence of alcohol consumption and IDU among HIV-infected people on HAART; to determine sociodemographic factors associated with alcohol abuse and IDU among people on HAART; and to determine impact of alcohol consumption and IDU on adherence to HAART.
The investigators will conduct a cross sectional study at the Yaoundé Central Hospital in Cameroon, from February to August 2015. Using a self-report questionnaire, the investigators will include at least 1,000 HIV-infected adults (18 years or more) on HAART for at least one month coming for HIV care. The investigators will exclude pregnant women. Data collection will include sociodemographic and economic profile, alcohol consumption using Alcohol Use Disorders Identification Test, injecting drug use, adherence to HAART using visual analog scale and self-rate report. The investigators will perform sub-analysis for sex group and area of habitation. A p value < 0.05 will be considered statistically significant.
There is a critical need of accurate estimates of the amplitude and the distribution of IDU and alcohol consumption among HIV-infected adults, in order to inform health policies maker for curbing burden of both injecting drug use and alcohol consumption among people living with HIV.
|Condition or disease|
Show Detailed Description
|Study Type :||Observational|
|Estimated Enrollment :||1000 participants|
|Official Title:||Prevalence, Socio-demographic Correlates of Substance Use Disorders Among HIV-infected Adults in Cameroon, and Their Influence on Adherence to Antiretroviral Therapy and Immunological Feature: Study Protocol for a Retrospective Cohort Study|
|Study Start Date :||September 2015|
|Estimated Primary Completion Date :||December 2015|
|Estimated Study Completion Date :||December 2015|
- Adherence to antiretroviral therapy [ Time Frame: All days up to 180 days ]The investigators will measure adherence to antiretroviral therapy using a linear visual analogue scale on the past month as primary method of measure
- Self-rate of adherence to antiretroviral therapy [ Time Frame: All days up to 180 days ]The investigators will measure adherence to antiretroviral therapy using self-rate by following scale: '1 - very good' to '5 - very bad'
- Alcohol consumption [ Time Frame: All days up to 180 days ]The investigators will use the Alcohol Use Disorders Identification Test (AUDIT) to identify subjects with at-risk, hazardous, or harmful drinking. AUDIT has a possible range from 0 to 40. A score ≤ 7 is classified as no current problem (low risk drinking), a score range between 8 - 15 is classified as probable current problem drinking (risky or hazardous drinking), a score range between 16 - 19 is classified as high risk or harmful drinking, and a score ≥ 20 as define harm and likely to be alcohol dependent. The investigators prefer to use self-reported questionnaire vs. interview questionnaire because it may produce more accurate answers, but patients who will not well understand a question, could ask more clarifications. The investigators will therefore use AUDIT screening instrument test to classify current drinkers as problem or non-problem drinkers at cut-off ≥ 8.
- Injecting drug use [ Time Frame: All days up to 180 days ]Patients will report if Yes or No, they have already used an injectable drug. If yes, they will give frequency and last time of use.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02356185
|Contact: Jean Joel R Bigna, MDemail@example.com|
|Principal Investigator:||Jean Joel R Bigna, MD||Goulfey Health District Unit|